Initiate European Phase I/II clinical study of AMT-130
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Oct 2021
- Due
- 31 Dec 2021
- Delivered
- 16 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company also remains on track to initiate a second Phase I/II clinical study of AMT-130 in Europe, with enrollment beginning before year-end 2021.”
What we found
Evidence strength A What the grades mean
The company initiated patient screening for the European Phase Ib/II study of AMT-130 on December 16, 2021, which meets the commitment to initiate the study before the end of 2021.
-
A uniQure N.V. 10-K filed 2022-02-25
“Also on December 16, 2021, we announced the initiation of patient screening in our 15 patient, open-label, Phase Ib/II study of AMT-130 in the EU” ✓ confirmed on the page
Market reaction: the shares moved +8.6% against the S&P 500 over the three sessions around the disclosure (24 Feb 2022 to 1 Mar 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- European Phase I/II clinical study of AMT-130
- Where
- Europe
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-001785 · Corrections policy